<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104131">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01819961</url>
  </required_header>
  <id_info>
    <org_study_id>Fo-Lap</org_study_id>
    <nct_id>NCT01819961</nct_id>
  </id_info>
  <brief_title>Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery</brief_title>
  <official_title>Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Zhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Run Run Shaw Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effect of postoperative parenteral fish oil on
      clinical outcome and immune function after major laparoscopic abdominal surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative patients are randomized by a sealed envelope to receive either a 50:50
      (vol/vol) mixture of an oil rich in medium-chain fatty acids and soybean oil (termed
      MCT/LCT) or a mixture of MCT/LCT and fish oil Omegaven for 7 days. Full blood count,
      biochemistry and coagulation are routinely assessed. Fresh blood samples are centrifuged
      into plasma, red blood cells and lymphocytes then stored at −80°C pending analysis.

      The primary endpoint was numbers of infective complications.Secondary endpoints were other
      clinical outcomes, length of hospital stay, and in-hospital mortality, along with plasma
      immunological markers.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>infective complications</measure>
    <time_frame>within the first 30 days after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>average of 2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma immunological markers</measure>
    <time_frame>from 1 day before surgery to 7 days after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastric Tumor</condition>
  <condition>Pancreatic Tumor</condition>
  <condition>Liver Tumor</condition>
  <arm_group>
    <arm_group_label>MCT/LCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Structural Fat Emulsion Injection 250ml per day, for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCT/LCT and fish oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Structural Fat Emulsion Injection 250ml and  fish oil 100ml for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCT/LCT and fish oil</intervention_name>
    <arm_group_label>MCT/LCT and fish oil</arm_group_label>
    <other_name>Structural Fat Emulsion Injection (Fresenius-Kabi, Germany) and fish oil (Omegaven,Fresenius-Kabi, Germany)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCT/LCT</intervention_name>
    <arm_group_label>MCT/LCT</arm_group_label>
    <other_name>Structural Fat Emulsion Injection (Fresenius-Kabi, Germany)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing an elective major laparoscopic abdominal surgery and required at
             least 5 days of parenteral nutrition

        Exclusion Criteria:

          -  Metabolic disease

          -  Chronic kidney or liver failure

          -  Shock

          -  Contraindications for lipid administration

          -  PN during the 15 days before hospitalisation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yiping Mou, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sir Run Run Shaw Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Zhou, MD,  PhD</last_name>
    <phone>+86-13588706479</phone>
    <email>nuzwlvran@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hosptial</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Zhou</last_name>
      <phone>+86-13588706479</phone>
      <email>nuzwlvran@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 27, 2013</lastchanged_date>
  <firstreceived_date>March 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sir Run Run Shaw Hospital</investigator_affiliation>
    <investigator_full_name>Wei Zhou</investigator_full_name>
    <investigator_title>Attending</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
